3 hours Revolution Medicines (NASDAQ:RVMD) Stock Rating Reaffirmed by Needham & Company LLCMarketBeat
Needham & Company LLC reiterated a “buy” rating and issued a $61.00 price target on shares of Revolution Medicines in a report on Thursday.
XNeedham & Company LLC reiterated a “buy” rating and issued a $61.00 price target on shares of Revolution Medicines in a report on Thursday.
X